Ken Griffin Myovant Sciences Ltd. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$24.03 - $27.02 $20.9 Million - $23.5 Million	-870,046 Reduced 89.69%	100,059 $2.7 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $16,344 - $28,799	1,409 Added 0.15%	970,105 $17.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.78 - $14.69 $2.48 Million - $4.68 Million	318,407 Added 48.96%	968,696 $12 Million
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $4.85 Million - $7 Million	426,569 Added 190.67%	650,289 $8.66 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $594,895 - $992,323	41,572 Added 22.82%	223,720 $3.48 Million
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $55,891 - $79,647	2,951 Added 1.65%	182,148 $4.09 Million
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $126,044 - $181,351	-7,384 Reduced 3.96%	179,197 $4.08 Million
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $4.3 Million - $5.3 Million	-210,294 Reduced 52.99%	186,581 $3.84 Million
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $3.92 Million - $7.84 Million	283,848 Added 251.13%	396,875 $11 Million
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $5.03 Million - $8.09 Million	-357,924 Reduced 76.0%	113,027 $1.59 Million
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $1.08 Million - $3.06 Million	146,693 Added 45.24%	470,951 $9.71 Million
Q1 2020 May 15, 2020	BUY	$6.55 - $14.76 $2.01 Million - $4.53 Million	306,835 Added 1761.09%	324,258 $2.45 Million
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $271,887 - $1.24 Million	-64,735 Reduced 78.79%	17,423 $271,000
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $592,111 - $1.08 Million	-114,087 Reduced 58.13%	82,158 $427,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $1.71 Million - $4.91 Million	196,245 New	196,245 $1.78 Million

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account